ADVANCED KRAS G12D MUTANT SOLID TUMORS
Clinical trials for ADVANCED KRAS G12D MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED KRAS G12D MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets 'Undruggable' cancer mutation in first human trial
Disease control OngoingThis is a first-in-human study to test the safety and side effects of a new drug called HRS-4642. It is for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. The main goals are to find a safe dose and see how the body processes the…
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug combo targets Tough-to-Treat cancer mutation
Disease control OngoingThis study is testing the safety and effectiveness of a new drug called HRS-4642 when given with other cancer medications. It is for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if this combination can help control the…
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC